Stockscreener 앱 받기
11.10
3.23%
-0.37
전일 마감가:
$11.47
열려 있는:
$11.65
하루 거래량:
215.41K
Relative Volume:
1.04
시가총액:
$323.29M
수익:
$69.21M
순이익/손실:
$-61.98M
주가수익비율:
-4.278
EPS:
-2.5947
순현금흐름:
$-9.61M
1주 성능:
-11.20%
1개월 성능:
-12.60%
6개월 성능:
-21.05%
1년 성능:
-2.46%
1일 변동 폭
$10.95
$11.65
1주일 범위
$10.95
$12.63
52주 변동 폭
$10.20
$17.15
Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile
명칭
Enanta Pharmaceuticals Inc
전화
617 607 0800
주소
4 KINGSBURY AVENUE, WATERTOWN, MA
Compare ENTA vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ENTA
Enanta Pharmaceuticals Inc
|
11.10 | 323.29M | 69.21M | -61.98M | -9.61M | -2.5947 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-26 | 개시 | Rodman & Renshaw | Buy |
| 2025-11-14 | 개시 | JP Morgan | Overweight |
| 2025-10-01 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-07-28 | 재개 | H.C. Wainwright | Buy |
| 2023-08-09 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-08-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-12-09 | 개시 | H.C. Wainwright | Buy |
| 2022-07-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2022-06-01 | 업그레이드 | Evercore ISI | Underperform → In-line |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-09-09 | 개시 | SVB Leerink | Mkt Perform |
| 2021-01-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2020-11-24 | 개시 | Evercore ISI | Underperform |
| 2020-08-28 | 재개 | ROTH Capital | Buy |
| 2020-08-26 | 개시 | Piper Sandler | Overweight |
| 2020-07-27 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2020-03-17 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2019-11-22 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-26 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2019-05-24 | 개시 | Wolfe Research | Outperform |
| 2019-04-23 | 업그레이드 | Berenberg | Hold → Buy |
| 2018-12-13 | 개시 | Berenberg | Hold |
| 2018-06-06 | 개시 | ROTH Capital | Buy |
| 2018-02-08 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-01-02 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-11-21 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-07-11 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2016-04-28 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | 재확인 | Barclays | Underweight |
| 2015-10-23 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2015-10-23 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
모두보기
Enanta Pharmaceuticals Inc 주식(ENTA)의 최신 뉴스
Enanta Pharmaceuticals stock fell 2.78 percent on October 5 - AD HOC NEWS
Enanta Pharmaceuticals Inc (9EP.SG) Analyst insights, Price targets and Recommendations - Yahoo Finance Australia
Enanta Pharmaceuticals stock gains 4.48 percent to EUR 11.65 - AD HOC NEWS
Layoff Tracker: Merck adds 53 jobs to New Jersey chopping block - BioSpace
How Enanta Pharmaceuticals Inc. (ENTA) Affects Rotational Strategy Timing - Stock Traders Daily
How Enanta Pharmaceuticals Inc. (ENTA) Affects Rotational Strategy Timing - Stock Traders Daily
Enanta Pharmaceuticals to Participate in September Investor Conferences - Moomoo
Enanta Pharmaceuticals stock falls 1.25 percent to USD 11.85 - AD HOC NEWS
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
ENTA Reiterated by HC Wainwright & Co. -- Price Target Maintained at $20 - GuruFocus
Enanta Pharmaceuticals stock rating reiterated at Buy by H.C. Wainwright - Investing.com Canada
Enanta Pharmaceuticals stock trades at USD 12.11 - AD HOC NEWS
Enanta Pharmaceuticals reports new STAT6 inhibitors - BioWorld News
Enanta Pharmaceuticals reports new STAT6 inhibitors - bioworld.com
The One-Carbon Mistake That Cost A Patent Its Priority Date - marketscreener.com
(ENTA) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
ENTA stock holds steady as Enanta Pharmaceuticals focuses on antiviral pipeline - AD HOC NEWS
Enanta Pharmaceuticals stock gains after new SEC filing and solid cash position - AD HOC NEWS
Enanta Pharmaceuticals to Participate in September Investor Conferences - finance.yahoo.com
Enanta stock holds in the low teens as investors look to recent trial and earnings progress - ad-hoc-news.de
Enanta Pharmaceuticals to Participate in September Investor Conferences - Business Wire
Enanta (ENTA) Watch: Finishes 2.59% Up at $13.47 for the Current Session; Boundary Watch: the Price Remains Bounded by the Supplied Support and ResistanceMoney Flow Index - vinanet.vn
Deep Track Capital, LP Trims Enanta Pharmaceuticals Inc (ENTA) S - GuruFocus
Enanta Pharmaceuticals Announces Q3 Fiscal 2026 Financial Results - Kalkine Media
Enanta Pharmaceuticals Inc (NASDAQ: ENTA) Share Price, ENTA Stock News, ENTA Share Price & Updates - Kalkine
Enanta Pharmaceuticals Inc (NASDAQ: ENTA) Share Price, ENTA Stock News, ENTA Share Price & Updates - kalkine.ca
H.C. Wainwright Maintains Enanta Pharmaceuticals(ENTA.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Enanta Pharma reports $19.5 million Q3 loss, advances RSV pipeline - scanx.trade
Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue Estimates - NewsBreak: Local News & Alerts
Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
Is Enanta Pharmaceuticals (ENTA) Overvalued After Q3 Earnings Mi - GuruFocus
Enanta Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Enanta Pharma misses Q3 estimates on lower royalty revenue By Investing.com - Investing.com Canada
Enanta Pharma misses Q3 estimates on lower royalty revenue By Investing.com - Investing.com South Africa
Enanta Fiscal Q3 2026 Earnings: Higher Royalty-Related Interest Expense Widens Net Loss - TradingKey
Enanta Pharma misses Q3 estimates on lower royalty revenue - Investing.com
Enanta Pharmaceuticals (NASDAQ:ENTA) Posts Earnings Results, Misses Expectations By $0.16 EPS - marketbeat.com
Enanta Pharmaceuticals reports Q3 loss; revenue $14.4M, cash and securities $211.5M - tradingview.com
Enanta Pharma On Track to File IND for EPS-3903, an Oral, Once-Daily STAT6 Inhibitor and to Select MRGPRX2 Development Candidate, in 2H >ENTA - Moomoo
Enanta Pharmaceuticals: Fiscal Q3 Earnings Snapshot - Barchart.com
Enanta Pharmaceuticals: Fiscal Q3 Earnings Snapshot - KTVB
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026 - Business Wire
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026 - finance.yahoo.com
Enanta Pharmaceuticals Inc expected to post a loss of 51 cents a shareEarnings Preview - TradingView
Enanta Pharmaceuticals (ENTA) Climbs 3.2% as Shares Test Key Resistance at $14.46Call Dominated - vinanet.vn
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
(ENTA) Risk Channels and Responsive Allocation - Stock Traders Daily
Enanta Pharmaceuticals (ENTA) Expected to Post Quarterly Earnings on Monday - MarketBeat
Enanta Pharmaceuticals Inc (ENTA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
ENTA|Enanta Pharmaceuticals Inc|Price:12.780|Chg%:-0.170 - TradingKey
Enanta Pharmaceuticals Inc (ENTA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Enanta Pharmaceuticals Inc 주식 (ENTA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Trout Harry R. III | See Remarks |
Dec 05 '25 |
Sale |
14.23 |
542 |
7,713 |
16,348 |
| Rottinghaus Scott T. | Chief Medical Officer |
Dec 05 '25 |
Sale |
14.23 |
798 |
11,356 |
21,792 |
| Luu Brendan | Chief Business Officer |
Dec 05 '25 |
Sale |
14.23 |
1,394 |
19,837 |
38,329 |
| Kieffer Tara Lynn | Chief Product Strategy Officer |
Dec 05 '25 |
Sale |
14.23 |
2,106 |
29,968 |
30,620 |
| Or Yat Sun | Chief Scientific Officer |
Dec 05 '25 |
Sale |
14.23 |
2,390 |
34,010 |
371,392 |
| Luly Jay R. | President and CEO |
Dec 05 '25 |
Sale |
14.23 |
4,743 |
67,493 |
858,026 |
| Luly Jay R. | Officer |
Dec 05 '25 |
Proposed Sale |
14.24 |
4,743 |
67,540 |
0 |
| Capps Kathleen S. | See Remarks |
Dec 02 '25 |
Sale |
13.96 |
207 |
2,890 |
8,700 |
| Trout Harry R. III | See Remarks |
Dec 02 '25 |
Sale |
13.96 |
380 |
5,305 |
16,890 |
4.22%
자본화:
|
볼륨(24시간):